Eb Haus Austria Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

The department is conducting research on breast cancer, specifically evaluating a new combination therapy to improve patient outcomes after surgery.

• HR‑positive, HER2‑negative early breast cancer
• Adjuvant ribociclib added to endocrine therapy
• Goal of increasing invasive disease‑free survival
• Assessment of safety and tolerability

At Eb Haus Austria Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH, investigators are testing whether adding ribociclib to standard endocrine treatment can extend iDFS for patients with HR‑positive, HER2‑negative early breast cancer.

Pediatric and young adult leukemia is being studied with an innovative chemo‑immunotherapy regimen that integrates targeted agents.

• Philadelphia chromosome‑positive B‑cell acute lymphoblastic leukemia
• ABL‑class Ph‑like B‑ALL
• Incorporation of blinatumomab into modified BFM chemotherapy
• Continuous tyrosine‑kinase inhibition (dasatinib or imatinib)
• Three‑year event‑free survival and safety monitoring

Researchers at the Salzburg site aim to estimate 3‑year EFS for children, adolescents and young adults with newly diagnosed Ph+ or ABL‑class Ph‑like B‑ALL treated with a modified chemotherapy backbone that includes three cycles of blinatumomab and continuous TKI therapy, while closely tracking toxicity and infection rates.